Citius Pharmaceuticals (NASDAQ:CTXR) announced on Tuesday it received a Nasdaq notification, indicating that the company regained compliance with Nasdaq's minimum bid price requirement rule of $1.00 per share for continued listing.
The company said the previously scheduled Nasdaq Hearing Panel has been cancelled. Nasdaq informed the company that Citius Pharma's securities will continue to be listed and traded on Nasdaq.